Phase I study of tenofovir alafenamide and its metabolite tenofovir in HIV–uninfected subjects with severe renal impairment versus matched-control subjects with normal renal function.

Trial Profile

Phase I study of tenofovir alafenamide and its metabolite tenofovir in HIV–uninfected subjects with severe renal impairment versus matched-control subjects with normal renal function.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Tenofovir alafenamide (Primary) ; Tenofovir
  • Indications HIV infections; Renal impairment
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2016 New trial record
    • 23 May 2016 Results published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top